Copyright
©The Author(s) 2021.
World J Hepatol. Dec 27, 2021; 13(12): 2113-2127
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2113
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2113
All patients, n = 75 | AIH, n = 54 | ASC, n = 21 | P value | |
Biochemical profile | ||||
AST U/L (NV ≤ 45) | 438 (129-982) | 678 (204-1200) | 150 (94-333) | < 0.001 |
GGT U/L (NV ≤ 50) | 116 (60-296) | 107 (54-196) | 360 (68-607) | < 0.001 |
Total bilirubin (NV ≤ 1 mg/dL) | 1.7 (0.6-4.5) | 2.7 (0.6-5.3) | 1.2 (0.7-2.5) | 0.05 |
ALP (NV ≤ 350 U/L) | 296 (204-469) | 283 (199-462) | 301 (242-494) | 0.328 |
ALP/AST ratio | 0.7 (0.3-2.2) | 0.4 (0.2-1.6) | 2.3 (0.7-3.5) | 0.002 |
Albumin (NV: 30-50 g/dL) | 42 (38-44) | 42 (37-44) | 42 (40-46) | 0.082 |
INR (NV: 0.9-1.2) | 1.2 (1.1-1.5) | 1.2 (1.1-1.6) | 1.1 (1.0-1.2) | < 0.05 |
Platelet (109/L) | 252 (180-350) | 234 (167-314) | 319 (251-393) | < 0.05 |
Autoimmune profile | ||||
ANA (≥ 1:20): n (%) | 55 (73) | 38 (70) | 17 (81) | 0.777 |
SMA (≥ 1:20): n (%) | 53 (71) | 38 (70) | 15 (71) | 1 |
Anti-LKM-1 (≥ 1:10): n (%) | 12 (16) | 12 (22) | 0 (0) | < 0.05 |
Anti-LC1: n (%) | 9 (12) | 9 (17) | 0 (0) | < 0.05 |
ANCA: n (%) | 37 (49) | 22 (41) | 15 (71) | < 0.05 |
IgG g/dL (NV: 0.5-1.8 g/dL) | 2.0 (1.4-3.2) | 2.3 (1.4-3.3) | 1.7 (1.5-2.2) | 0.325 |
IgG > ULN: n (%) | 51 (68) | 37 (69) | 14 (67) | 1 |
Histology, n (%) | ||||
Interface hepatitis | 51 (68) | 42 (78) | 12 (57) | 0.09 |
Fibrosis | 61 (81) | 42 (78) | 19 (90) | 0.324 |
Cirrhosis | 17 (23) | 15 (28) | 2 (10) | 0.127 |
Features of biliopathy1 | 62 (83) | 37 (68) | 17 (81) | 0.764 |
- Citation: Di Giorgio A, Tulone A, Nicastro E, Norsa L, Sonzogni A, D'Antiga L. Use of oral vancomycin in children with autoimmune liver disease: A single centre experience. World J Hepatol 2021; 13(12): 2113-2127
- URL: https://www.wjgnet.com/1948-5182/full/v13/i12/2113.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i12.2113